<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32571900</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-6244</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of medical genetics</Title><ISOAbbreviation>J Med Genet</ISOAbbreviation></Journal><ArticleTitle>Wide range of reduced penetrance alleles in spinal and bulbar muscular atrophy: a model-based approach.</ArticleTitle><Pagination><StartPage>385</StartPage><EndPage>391</EndPage><MedlinePgn>385-391</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jmedgenet-2020-106963</ELocationID><Abstract><AbstractText Label="BACKGROUND">Spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's disease, is an X-linked motor neuron disorder caused by an expanded CAG repeat in the gene coding for the androgen receptor (AR). The range and significance of reduced penetrance alleles in SBMA has not been fully determined to date. We presently sought to determine the range of reduced penetrance alleles in SBMA.</AbstractText><AbstractText Label="METHODS">Through systematic literature review and meta-analysis, we collected and analysed data from 2576 patients with SBMA and compared the distributions of the CAG repeat number (CAG)<sub>n</sub> in the AR gene between patients and 112&#x2009;248 control alleles of the general population.</AbstractText><AbstractText Label="RESULTS">Our analysis revealed an unexpectedly high frequency of expanded SBMA-associated alleles, with (CAG)<sub>n</sub> &#x2265;35 present in 107/100,000 and (CAG)<sub>n</sub> &#x2265;38 present in 27/100,000 of the general population. Consequently, we suggest an updated model describing the distribution of expanded alleles in the general population. We argue against the established cut-off principle for the penetrance of SBMA and suggest that penetrance gradually increases from 35 to approximately 46 (CAG)<sub>n</sub>, above which it reaches a plateau approaching maximum value.</AbstractText><AbstractText Label="CONCLUSION">Asymptomatic men of the general population with no/unknown SBMA family history are free of risk when carrying (CAG)<sub>n</sub> &#x2264;34, are at intermediate but increasing risk for developing SBMA when carrying (CAG)<sub>n</sub> &#x2248;35-46 and have close to 100% risk of developing the disease when carrying (CAG)<sub>n</sub> &#x2265;47. The above observations should be helpful and clinically useful when providing genetic counselling to individuals and families bearing SBMA-associated alleles.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laskaratos</LastName><ForeName>Achilleas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurogenetics Unit, 1st Department of Neurology, National and Kapodistrian University of Athens, Eginition University Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breza</LastName><ForeName>Marianthi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurogenetics Unit, 1st Department of Neurology, National and Kapodistrian University of Athens, Eginition University Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karadima</LastName><ForeName>Georgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neurogenetics Unit, 1st Department of Neurology, National and Kapodistrian University of Athens, Eginition University Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koutsis</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-8980-8377</Identifier><AffiliationInfo><Affiliation>Neurogenetics Unit, 1st Department of Neurology, National and Kapodistrian University of Athens, Eginition University Hospital, Athens, Greece gkoutsi2@otenet.gr gkoutsis@med.uoa.gr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Med Genet</MedlineTA><NlmUniqueID>2985087R</NlmUniqueID><ISSNLinking>0022-2593</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008540" MajorTopicYN="N">Meiosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008957" MajorTopicYN="N">Models, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019683" MajorTopicYN="Y">Penetrance</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">clinical genetics</Keyword><Keyword MajorTopicYN="N">neurology</Keyword></KeywordList><CoiStatement>Competing interests: GKa has received research grants from Pfizer and provided consultation services for Roche. GKo has received research grants from Teva and Genesis Pharma and provided consultation services for and/or received honoraria from Novartis, Sanofi-Genzyme, Genesis Pharma, Specifar, Pfizer, Roche, Teva, Merck and Integris Pharma.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32571900</ArticleId><ArticleId IdType="doi">10.1136/jmedgenet-2020-106963</ArticleId><ArticleId IdType="pii">jmedgenet-2020-106963</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>